14.74
-0.12 (-0.77%)
| Previous Close | 14.85 |
| Open | 14.84 |
| Volume | 1,158,732 |
| Avg. Volume (3M) | 2,452,921 |
| Market Cap | 4,632,137,216 |
| Price / Earnings (TTM) | 1,473.50 |
| Price / Sales | 1.50 |
| 52 Weeks Range | |
| Earnings Date | 27 Feb 2026 |
| Profit Margin | -0.46% |
| Operating Margin (TTM) | 14.51% |
| Diluted EPS (TTM) | -0.040 |
| Quarterly Revenue Growth (YOY) | 5.50% |
| Quarterly Earnings Growth (YOY) | -49.70% |
| Current Ratio (MRQ) | 1.40 |
| Operating Cash Flow (TTM) | 306.92 M |
| Levered Free Cash Flow (TTM) | 311.48 M |
| Return on Assets (TTM) | 6.67% |
| Return on Equity (TTM) | -881.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Amneal Pharmaceuticals, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 46.75% |
| % Held by Institutions | 43.76% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Jan 2026 | Announcement | Amneal Pharmaceuticals Added to S&P SmallCap 600® Index |
| 27 Jan 2026 | Announcement | TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600 |
| 27 Jan 2026 | Announcement | Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026 |
| 09 Jan 2026 | Announcement | KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson’s Disease |
| 22 Dec 2025 | Announcement | Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA® |
| 09 Dec 2025 | Announcement | Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |